相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab
Fernando Rivera et al.
ACTA ONCOLOGICA (2008)
Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000)
Joan H. Schiller
CANCER INVESTIGATION (2008)
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2008)
Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes
Paul Wheatley-Price et al.
CURRENT OPINION IN ONCOLOGY (2008)
ErbB-directed immunotherapy:: Antibodies in current practice and promising new agents
Elza Friedlander et al.
IMMUNOLOGY LETTERS (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer
James J. Lee et al.
CLINICAL COLORECTAL CANCER (2007)
Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer
Marco Volante et al.
CANCER (2007)
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
J. Randolph Hecht et al.
CANCER (2007)
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer
Pasi A. Jaenne et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer
Erner O. Hanrahan et al.
CLINICAL CANCER RESEARCH (2007)
Erlotinib in non-small cell lung cancer treatment: Current status and future development
Cesare Gridelli et al.
ONCOLOGIST (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma
Yoshihiko Kawaguchi et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rational bases for the development of EGFR inhibitors for cancer treatment
Roberto Bianco et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations
Marianela Perez-Torres et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The epidermal growth factor receptor pathway: A model for targeted therapy
Maurizio Scaltriti et al.
CLINICAL CANCER RESEARCH (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival
O Cochet et al.
CELLULAR SIGNALLING (2006)
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib
N Yoshimura et al.
LUNG CANCER (2006)
Oncogenic PI3K and its role in cancer
Y Samuels et al.
CURRENT OPINION IN ONCOLOGY (2006)
Phospholipase C-γ:: diverse roles in receptor-mediated calcium signaling
RL Patterson et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
ras oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells -: Epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation
ZP Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
FDA drug approval summary:: Erlotinib (Tarceva®) tablets
MH Cohen et al.
ONCOLOGIST (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression
GL Johnson et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma
P Sunpaweravong et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
The activation of Akt/PKB signaling pathway and cell survival
G Song et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2005)
Genetic analysis of the kinome and phosphatome in cancer
S Arena et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2005)
Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor α stimulation is counteracted by nuclear factor κB through c-FLIP-L expression
V Benoit et al.
CANCER RESEARCH (2004)
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
KA Foon et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivoi
MK Nyati et al.
CLINICAL CANCER RESEARCH (2004)
p53 upregulates death receptor 4 expression through an intronic p53 binding site
XG Liu et al.
CANCER RESEARCH (2004)
EGFR-induced cell migration is mediated predominantly by the JAK-STAT pathway in primary esophageal keratinocytes
CD Andl et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2004)
Active and inactive conformations of the epidermal growth factor receptor
KM Ferguson
BIOCHEMICAL SOCIETY TRANSACTIONS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy
WK Bleeker et al.
JOURNAL OF IMMUNOLOGY (2004)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess et al.
MOLECULAR CELL (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
R Bianco et al.
ONCOGENE (2003)
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment
N Normanno et al.
ENDOCRINE-RELATED CANCER (2003)
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy
A Citri et al.
EMBO JOURNAL (2002)
Epidermal growth factor receptor biology (IMC-C225)
ES Kim et al.
CURRENT OPINION IN ONCOLOGY (2001)
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human cancer cell lines
F Ciardiello et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
EGF mutant receptor vIII as a molecular target in cancer therapy
CT Kuan et al.
ENDOCRINE-RELATED CANCER (2001)
The role of EGF-related peptides in tumor growth
N Normanno et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2001)
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
XD Yang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
The epidermal growth factor receptor as a target for cancer therapy
J Mendelsohn
ENDOCRINE-RELATED CANCER (2001)
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells
P O-charoenrat et al.
CLINICAL & EXPERIMENTAL METASTASIS (2000)
ZD1839 ('Iressa')(1,2) as an anticancer agent
J Baselga et al.
DRUGS (2000)
分享论文
